What is HC Wainwright’s Estimate for Myomo FY2030 Earnings?

Myomo, Inc. (NYSEAMERICAN:MYO) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Myomo in a report issued on Tuesday, March 10th. HC Wainwright analyst S. Lee expects that the company will earn $0.35 per share for the year. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share.

A number of other equities analysts have also weighed in on the stock. Craig Hallum reiterated a “buy” rating on shares of Myomo in a research report on Tuesday. Ascendiant Capital Markets dropped their price target on shares of Myomo from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $7.67.

Myomo Trading Down 16.8%

Shares of MYO opened at $0.68 on Wednesday. Myomo has a fifty-two week low of $0.64 and a fifty-two week high of $6.30. The business has a 50-day moving average of $0.86 and a 200 day moving average of $0.92. The firm has a market cap of $25.95 million, a P/E ratio of -1.82 and a beta of 1.17. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.10 and a current ratio of 2.49.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. grew its holdings in Myomo by 1.3% during the 4th quarter. Rosalind Advisors Inc. now owns 3,839,772 shares of the company’s stock valued at $3,494,000 after buying an additional 48,984 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of Myomo in the fourth quarter worth about $641,000. Geode Capital Management LLC boosted its position in shares of Myomo by 160.8% in the second quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock valued at $1,446,000 after acquiring an additional 412,631 shares during the period. Stonepine Capital Management LLC boosted its position in shares of Myomo by 65.3% in the second quarter. Stonepine Capital Management LLC now owns 457,419 shares of the company’s stock valued at $988,000 after acquiring an additional 180,712 shares during the period. Finally, AQR Capital Management LLC grew its stake in Myomo by 47.8% during the fourth quarter. AQR Capital Management LLC now owns 434,376 shares of the company’s stock valued at $395,000 after acquiring an additional 140,427 shares in the last quarter. Institutional investors own 44.99% of the company’s stock.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.